Bio-Techne (TECH) CFO exercises awards, covers taxes in stock
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) CFO James Hippel reported multiple equity-award transactions on 8/15/2026. He acquired 9,779 shares of common stock through exercises or conversions of restricted stock units, and 4,310 shares of common stock were delivered or withheld at $72.40 per share for payment of exercise price or tax liability. The board authorized discretionary vesting of 866 performance RSUs and 2,332 performance options, with the remaining related performance awards forfeited. Hippel continues to hold several option and RSU awards over BIO-TECHNE common stock with exercise prices ranging from $53.60 to $120.46 and expirations extending to 2035-08-15.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,469 shares
Net Buy
16 txns
Insider
Hippel James
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Restricted Stock Units F2, F3 | 866 | $0.00 | $0.00 |
| Disposition | Performance Restricted Stock Units F2, F3 | 12,999 | $0.00 | $0.00 |
| Disposition | Performance Stock Options (Right to Buy) F4 | 34,982 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F2, F7 | 4,010 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F2, F11 | 4,903 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,779 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 4,310 | $72.40 | $312K |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F6 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F8 | -- | -- | -- |
| holding | Restricted Stock Units F2, F9 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F10 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F12 | -- | -- | -- |
Holdings After Transaction:
Performance Restricted Stock Units — 53,482 shares (Direct);
Performance Stock Options (Right to Buy) — 2,332 shares (Direct);
Restricted Stock Units — 36,907 shares (Direct);
Common Stock — 170,183 shares (Direct);
Stock Options (Right to Buy) — 369,056 shares (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited.
- F4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,332 performance options. The remainder of the performance options were forfeited.
- F5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
- F8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Common shares acquired via exercise: 9,779 shares
Shares delivered/withheld for exercise price or tax: 4,310 shares
Performance RSUs vested: 866 units
+5 more
8 metrics
Common shares acquired via exercise
9,779 shares
Common Stock, code M on 2026-08-15
Shares delivered/withheld for exercise price or tax
4,310 shares
Common Stock, code F at $72.40 per share on 2026-08-15
Performance RSUs vested
866 units
Discretionary vesting authorized 2026-08-15; remainder forfeited
Performance options vested
2,332 options
Discretionary vesting authorized 2026-08-15; remainder forfeited
Largest reported option block
167,328 underlying shares at $66.97
Stock Options (Right to Buy), expiration 2027-08-05
Lowest option exercise price
$53.60
Stock Options (Right to Buy), 37,632 underlying shares, expiration 2035-08-15
Highest option exercise price
$120.46
Stock Options (Right to Buy), 40,536 underlying shares, expiration 2028-08-06
Option expiration range
2027-08-05 to 2035-08-15
Reported stock option awards held by CFO
Key Terms
Performance Restricted Stock Units, Restricted Stock Units, Stock Options (Right to Buy), exercise price, +2 more
6 terms
Performance Restricted Stock Units financial
"Performance Restricted Stock Units, underlyingSecurityTitle Common Stock"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy), underlyingShares 167328.0000"
exercise price financial
"conversion_or_exercise_price 66.9700, 120.4600, 94.5200, 84.6100, 53.6000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"authorized discretionary vesting for 866 performance RSUs"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
performance goals financial
"Vests in full or in part if certain performance goals are achieved"
Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.
FAQ
What insider transactions did TECH CFO James Hippel report on 8/15/2026?
On 8/15/2026, CFO James Hippel reported exercising awards to acquire 9,779 TECH common shares and delivering or withholding 4,310 shares at $72.40 per share to cover exercise price or tax liability, alongside performance award vesting and forfeitures.
What performance RSUs and options vested or were forfeited for TECH’s CFO?
On 8/15/2026, BIO-TECHNE’s board authorized discretionary vesting of 866 performance RSUs and 2,332 performance options for the CFO. The remaining RSUs and options in those specific performance awards were forfeited as disclosed in the footnotes.
What option positions does the TECH CFO retain after these transactions?
The CFO retains several stock option awards over BIO-TECHNE common stock, including 167,328 underlying shares at $66.97, 45,220 at $94.52, and other tranches with exercise prices up to $120.46, expiring between 2027 and 2035.
Do the TECH equity awards for the CFO include future performance-based vesting?
Yes. Certain performance restricted stock units for BIO-TECHNE’s CFO vest in full or part on 8/15/2027 and 8/15/2028 if specified performance goals are achieved, with vesting timing tied to later certification by the plan administrator.
AI-generated analysis. How Rhea-AI works. Not financial advice.
